Page 326«..1020..325326327328..340350..»

Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study – NutraIngredients-Asia

Posted: July 27, 2022 at 3:09 am

The study was conducted by Hanyang University, with the findings published in Nutrients recently.

It assessed the relationship between micronutrient intake and breast cancer risk using a standardised semi-quantitative food frequency questionnaire (FFQ).

A total of 103 food items, excluding dietary supplements, were included in the FFQ to assess the womens intake of micronutrients from their diets.

A total of 40,432 women without a history of cancer were included to take part in the survey. These women were selected to take part in the survey based on the Korean Genome and Epidemiology Study (KoGES).

After completing the survey, the researchers followed up on these women for an average of 4.9 years.

By the end of the follow-up, a total of 232 women reported that they had been diagnosed with breast cancer by a physician.

Breast cancer was the most common cancer in women, accounting for 23,647 (20.5%) cases of cancer, according to the 2018 cancer registration statistics in South Korea.

Risk factors include the lifestyle, the level of physical activity, alcohol consumption, as well as the age at which they gave birth, the number of births, breastfeeding experience and duration, and the use of hormone replacement therapy after menopause.

Findings showed that the intake of vitamin C and vitamin B6 above the daily recommended value based on the 2020 Dietary Reference Intakes for Koreans (KDRIs) was associated with a reduced risk in obese women.

However, no significant association was not observed in women with normal weight.

Obesity is associated with higher estrogen levels in postmenopausal women due to the aromatase change of testosterone to estrogen in adipose tissue, as well as chronic inflammation status with increased oxidative stress permanently.

Thus, the antioxidant effect of vitamin C may be more prominent in women with obesity, the researchers explained.

As for the impact seen from vitamin B6, the researchers said this could be because the vitamin was involved in insulin resistance and could control adipogenesis-related genes, or fat-related genes.

A protective association of high vitamin B6 intake was observed only in obese women. Studies have suggested that vitamin B6 is also involved in insulin resistance by controlling the expression of adipogenesis-related genes. Thus, the protective effect may be more prominent in women with obesity.

The research was supported by a National Research Foundation of Korea grant funded by the South Korean government.

Source: Nutrients

Association between Micronutrient Intake and Breast Cancer Risk According to Body Mass Index in South Korean Adult Women: A Cohort Study

https://doi.org/10.3390/nu14132644

Authors: Song, H.; Jeong, A.; Tran, T.X.M.; Lee, J.; Kim, M.; Park, B.

Read the original:
Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study - NutraIngredients-Asia

Posted in Testosterone Replacement Therapy | Comments Off on Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study – NutraIngredients-Asia

Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of…

Posted: July 27, 2022 at 3:07 am

  1. Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of Physicians | Annals of Internal Medicine  Annals of Internal Medicine
  2. Genetic Testing Should Be Guided by Patients' Best Interests, ACP Position Paper Says  GenomeWeb
  3. ACP offers guidance on the ethical use of genetic testing and precision medicine  EurekAlert
  4. The Ethical Responsibilities of Precision Medicine According to ACP  MD Magazine
  5. View Full Coverage on Google News

See the original post:
Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of...

Posted in Genetic medicine | Comments Off on Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of…

Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS – PR Newswire

Posted: July 27, 2022 at 3:07 am

CARLSBAD, Calif., July 26, 2022 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational antisense medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS). The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a Prescription Drug User Fee Act action date of Jan. 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application. The average life expectancy for people with ALS is three to five years from time of symptom onset; patients with some SOD1 mutations have an even shorter life expectancy. There is currently no treatment targeted for SOD1-ALS.

"Acceptance of the new drug application for tofersen is a monumental milestone, not just for Ionis but for all people with SOD1-ALS, their families and healthcare professionals battling this devastating disease. To them we extend our deepest gratitude. Their courage has been instrumental to the achievement of this goal," said C. Frank Bennett, Ph.D., executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis. "We also want to thank Biogen for their commitment to advancing tofersen, which, if approved, will be the first treatment that targets a genetic cause of ALS." Dr. Bennett added, "Acceptance of the NDA for tofersen further strengthens Ionis' platform strategy to target all forms of ALS and central nervous system disorders more broadly."

Biogen is seeking approval of tofersen under the FDA's accelerated approval pathway, based on the use of neurofilament as a surrogate biomarker that is reasonably likely to predict clinical benefit. Neurofilaments are normal proteins found in healthy neurons, that are increased in blood and cerebrospinal fluid when damage has been done to neurons or their axons and are a marker of neurodegeneration. In ALS, higher levels of neurofilaments have been found to predict more rapid decline in clinical function and shortened survival. Tofersen study results suggest reductions in neurofilament preceded and predicted slowing of decline in measures of clinical and respiratory function, strength and quality of life. Biogen has stated its commitment to ongoing data generation and finalizing the confirmatory package with the FDA.

The tofersen NDA included results from a Phase 1 study in healthy volunteers, a Phase 1/2 study evaluating ascending dose levels, the Phase 3 VALOR study, and the open label extension (OLE) study. Also included are the most current 12-month integrated results from VALOR and the OLE study, recently presented at the European Network to Cure ALS (ENCALS) annual meeting.

As reported in October 2021, VALOR, a six-month Phase 3 randomized study, did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. However, trends of reduced disease progression across multiple secondary and exploratory endpoints were observed. The 12-month VALOR and OLE integrated data showed that earlier initiation of tofersen led to sustained reductions in neurofilament, a marker of neurodegeneration, and slowed decline across multiple efficacy endpoints.

In the 12-month data, the most common adverse events (AEs) in participants receiving tofersen in VALOR and the OLE study were headache, procedural pain, fall, back pain and pain in extremities. Most AEs in both VALOR and the OLE were mild to moderate in severity. Serious AEs were reported in 36.5 percent of participants who received tofersen in VALOR and/or the OLE and 17.3 percent of participants discontinued treatment due to an AE.

During the FDA review period Biogen will maintain its early access program for tofersen, now with participants in over a dozen countries. The open-label extension and Phase 3 ATLAS study in presymptomatic individuals with a SOD1 genetic mutation remain ongoing. Biogen is actively engaging with other regulators around the world and will provide updates when appropriate.

About Tofersen

Tofersen is an antisense medicine being evaluated for the potential treatment of SOD1-ALS. Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H in an effort to reduce synthesis of SOD1 protein production. In addition to the ongoing open label extension of VALOR, tofersen is being studied in the Phase 3 ATLAS study designed to evaluate whether tofersen can delay clinical onset when initiated in presymptomatic individuals with a SOD1 genetic mutation and biomarker evidence of disease activity. Biogen licensed tofersen from Ionis under a collaborative development and license agreement.

About Amyotrophic Lateral Sclerosis and SOD1-ALS

Amyotrophic lateral sclerosis (ALS) is a rare, progressive and fatal neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord that are responsible for controlling voluntary muscle movement. People with ALS experience muscle weakness and atrophy, causing them to lose independence as they steadily lose the ability to move, speak, eat, and eventually breathe. Average life expectancy for people with ALS is three to five years from time of symptom onset. Patients with some SOD1 mutations have an even shorter life expectancy.

Multiple genes have been implicated in ALS. Genetic testing helps determine if a person's ALS is associated with a genetic mutation, even in individuals without a family history of the disease. Currently, there are no genetically targeted treatment options for ALS. Mutations in the SOD1 gene are responsible for approximately 2 percent of the estimated 168,000 people who have ALS globally (SOD1-ALS).

AboutIonis Pharmaceuticals, Inc.

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.

To learn more about Ionis visit http://www.ionispharma.com and follow us on Twitter @ionispharma.

Ionis' Forward-looking Statements

This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, tofersen and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers toIonis Pharmaceuticalsand its subsidiaries.

Ionis Pharmaceuticals is a trademark ofIonis Pharmaceuticals, Inc.

SOURCE Ionis Pharmaceuticals, Inc.

Read more:
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS - PR Newswire

Posted in Genetic medicine | Comments Off on Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS – PR Newswire

Startup aiming to push boundaries of gene therapy nets $55M in seed cash – MedCity News

Posted: July 27, 2022 at 3:07 am

Genetic medicines have a capacity problem. The engineered viruses used to deliver them have limited room for their genetic cargo, which in turn limits the way diseases can be treatedif they can be treated at all. A new biotech company named Replay has assembled a suite of technologies that could enable it to deliver big genes or even multiple genes, and it has emerged with $55 million to advance its research.

The seed round announced Monday was led by KKR & Co. and OMX Ventures.

The delivery vehicle of choice for many experimental genetic medicines is the adeno-associated virus (AAV), which can be engineered to ferry DNA to target cells. The capacity of AAV is just under 5 kilobases (kb). San Diego-based Replay claims it can achieve a payload capacity up to 30 times greater. It aims to do so with its synHSV technology, which employs an engineered herpes simplex virus (HSV). In addition, Replays toolkit includes technologies that enable it to efficiently write its big genes and big DNA, and a technology that can produce off-the-shelf therapies.

The capacity limitation of AAV is apparent in the research of genetic medicines for Duchenne muscular dystrophy. Sarepta Therapeutics, Solid Biosciences and Pfizer have reached clinical testing with their respective gene therapies, each one engineered to deliver a functioning version of the gene needed to treat the inherited muscle-wasting disorder. But the genes that produce the key protein at the root of Duchenne are big, so the therapies are comprised of micro versions of the gene small enough to fit on an AAV vector.

Duchenne is one of the disease targets of Replay. The therapy in development for that muscle-weakening disorder is 14 kb, according to the companys website. But Replay wont be going directly head to head against the field of potential gene therapies for Duchenne. Under Replays business model, the various technologies it owns are developed in a disease-agnostic way. When Replay identifies an area that can specifically be addressed by one or more of its technologies, it forms a product company to pursue that area. The Duchenne research is housed in one such product company.

Technology and product development have different talent requirements, timelines, costs and cultures, Replay CEO and co-founder Lachlan MacKinnon said in a prepared statement. By separating technology development from product development, we have generated a model to accommodate these differences. Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.

Replay says it has formed five product companies to date. In the eye, one company is focused on retinitis pigmentosa, a group of rare retinal disorders that leads to degeneration of photoreceptors. The Replay website lists two gene therapy constructs for retinitis pigmentosa: one is 7 kb and the other is 9 kb. A Replay skin product company is developing a treatment for dystrophic epidermolysis bullosa, an inherited disorder that leads to extremely fragile skin that is prone to widespread blistering. The experimental therapy of that company is 19.2 kb. Replays brain product company has the biggest of its genetic medicines in development, a 40 kb therapy for Parkinsons disease. A fifth product company is focused on enzyme writing.

There are other startups that, like Replay, are turning to AAV alternatives in the quest for better genetic medicines. Last month, Philadelphia-area startup Code Bio closed a $75 million Series A round of funding to support the development of synthetic DNA-based therapies for two lead indications, Duchenne and type 1 diabetes.

The new round of financing for Replay included participation from Artis Ventures, Lansdowne Partners, SALT, DeciBio Ventures and Axial.

Photo: iLexx, Getty Images

Read the original here:
Startup aiming to push boundaries of gene therapy nets $55M in seed cash - MedCity News

Posted in Genetic medicine | Comments Off on Startup aiming to push boundaries of gene therapy nets $55M in seed cash – MedCity News

SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding Platform – BioSpace

Posted: July 27, 2022 at 3:07 am

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the expansion of its leadership team with the addition of five highly accomplished scientists, physicians and biotech industry leaders. The companys new appointments include:

As we continue to build on our foundational scientific discoveries and propel our research and development activities toward the clinic, we welcome Cathryn, Pat, Joe, Feng and Oleg to help drive our progress. The additions of these esteemed experts, each distinguished in their respective specialties, will serve to accelerate our growth by supporting core R&D activities, clinical preparations, and quality and operational needs, said Ray Tabibiazar, M.D., chief executive officer and chairman of SalioGen. We look forward to benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world.

Cathryn Clary, M.D., MBA previously served as Senior Vice President of Medical at SSI Strategy, a medical consulting firm. She also served as the acting Chief Medical Officer at clinical-stage gene therapy company Solid Biosciences. Dr. Clary served as both Global Head of Policy and Patient Affairs in the Chief Medical & Patient Safety Office, as well as Chief Scientific Officer and Head of U.S. Medical Affairs and Clinical Development in the General Medicines Division at Novartis. Prior to her experience at Novartis, she served in several executive roles at Pfizer, whereshe was responsible for the medical aspects of Zoloft worldwide, and ultimately became the SVP of US Medical Affairs for the entire Pfizer portfolio across multiple therapeutic areas.

Pat Sacco is highly experienced as a biotechnology and life sciences executive in technical and general operations. Most recently, as an independent consultant, he has worked with a number of advanced therapy medicinal product (ATMP) biotech companies, CDMOs, and specialized program management clients. Previously, he was the Senior Vice President of Technical Operations at both Translate Bio and Shire (now Takeda), and prior to that held roles of increasing responsibility at Wyeth Biopharma (formerly Genetics Institute) and Genzyme. He has contributed to the development, manufacturing, and commercialization of the enzyme replacement therapies REPLAGAL, ELAPRASE, and VPRIV.

Joe Senn, Ph.D. has experience with nearly all therapeutic modalities, including small molecules, biologics, antisense, gene editing and mRNA therapeutics. He most recently served as the Vice President of Nonclinical Development at Moderna Therapeutics for eight years, where he and his team were responsible for progressing over 40 candidates into the clinic. Prior to Moderna, Dr. Senn served as Site Head for Drug Safety at Takeda Pharmaceuticals, where he oversaw development of all immunology products across the portfolio.

Feng Yao, Ph.D. is the inventor of Invitrogen/Thermo Fisher Scientifics T-Rex tetracycline gene switch, a powerful and specific mammalian transcription gene switch. Using this technology, Dr. Yao has established several unique approaches for the genetic engineering of novel recombinant viruses for use in clinical applications across infectious diseases, cancers and neural regeneration. His T-REx technology is widely used and referenced in publications and patent applications, including productions of several FDA approved antibody therapeutics and novel COVID-19 viral vector-based vaccine candidates developed by AstraZeneca and Johnson and Johnson. Before joining SalioGen Therapeutics, Dr. Yao was an Associate Professor of Surgery at the Brigham and Womens Hospital and Harvard Medical School.

Oleg Iartchouk, Ph.D. has built and led multiple genomics technologyteams that werepart ofstartup and large global pharmaceutical and biotechnologycompanies.Prior to joining SalioGen, Dr. Iartchouk served as the Global Head of the global Genomics Platform Group at the Novartis Institute for Biomedical Research, which established genomics applications several fields to advance Novartiss cell and gene therapy portfolioincluding CAR-T cell(Kymriah) and gene (Zolgensma) therapies.Dr. Iartchouk also built the Biomarkers Discovery group at the clinical diagnostics company Natera and the Applied Genomics team at Sanofi Oncology.

About SalioGen TherapeuticsSalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines. SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on inherited macular disorders and inherited lipid disorders.

For more information, please visit http://www.saliogen.com, or follow us on Twitter and LinkedIn.

Forward-Looking StatementsThis press release contains forward-looking statements. Words such as may, believe, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are based upon current estimates and assumptions and include statements regarding the additions of the esteemed experts serving to accelerate SalioGens growth by supporting core research & development activities, clinical preparations, and quality and operational needs, benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world, and the potential of SalioGens Gene Coding approach, including its use in potentially curative genetic medicines. While SalioGen believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of SalioGen to position multiple therapeutic programs for clinical development, the ability of SalioGen to continue building out its Gene Coding platform, expand the companys team, establish manufacturing and automation capabilities critical for Gene Coding and accelerate the advancement of SalioGens preclinical programs as planned, the ability of SalioGen to use its Gene Coding platform and Exact DNA Integration Technology in potentially curative genetic medicines. All forward-looking statements are based on SalioGens expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, SalioGen expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Corporate Contact:Sung You, M.S., MBASalioGen Therapeuticsinvestors@saliogen.com

Media Contact:Amy Jobe, Ph.D.LifeSci Communications315-879-8192ajobe@lifescicomms.com

Read this article:
SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding Platform - BioSpace

Posted in Genetic medicine | Comments Off on SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding Platform – BioSpace

Orivet Partners with Sitruna to Expand Ecommerce Footprint in Europe – PR Web

Posted: July 27, 2022 at 3:07 am

Were thankful to be able to partner with Sitruna to bring accurate genetic pet testing to more pet owners in Europe, said Noam Pik, CEO of Orivet

LAKE WORTH, Fla. (PRWEB) July 26, 2022

Orivet, a pioneer in international genetic pet testing and personalized medicine announced its recent partnership with Sitruna, an Amazon logistics and marketing specialist company that specializes in leveraging its experience and industry knowledge to help create and meet demand on Amazon.

This new partnership will center around the growing demand for Orivets pet and breeder products on Amazon in Europe. As specialists in listing and logistics, Sitruna will help Orivet connect with pet owners, breeders, and veterinarians who are looking for evidence-backed and comprehensive methods to discover a pets genetic makeup, possible hereditary diseases, and health requirements.

With diseases such as obesity and other inherited variants becoming more scrutinized by pet owners in Europe, the demand for accurate hereditary genetic testing has skyrocketed in recent years with an expectation for the global market to reach $28.5 billion by 2026 a substantial increase from the $990 million valuation in 2020.

Were thankful to be able to partner with Sitruna to bring accurate genetic pet testing to more pet owners in Europe, said Noam Pik, CEO of Orivet.More people than ever are conscious of their pets long-term journey and want whats best for them, and we want to help these owners better map out a healthier life for their best friend.

About Orivet Genetic Pet CareOrivet Genetic Pet Care is a leading personalized-medicine organization offering innovative health care solutions for breeders, veterinarians, and pet owners. The organization was founded in 2010, on the premise that each pet is unique, with its own set of specific traits, behaviors, genetic health needs, and inherent risks. Orivet works with veterinarians, pet owners, and responsible pet breeders to provide practical, evidence-based platforms focused on identifying risk and improving clinical outcomes.For more information please visit https://www.orivet.com

About Sitruna Sitruna is an innovative IT services company that leverages its knowledge of listing optimization, PPC, photography, and logistics to help businesses gain market share, stay ahead of their competition, and maximize ROI on Amazon. Backed by decades of experience in eCommerce and numerous Amazons Choice badges, Sitruna backs up its five-star reviews with five-star results.For more information please visit https://www.sitruna.com

Share article on social media or email:

Read more here:
Orivet Partners with Sitruna to Expand Ecommerce Footprint in Europe - PR Web

Posted in Genetic medicine | Comments Off on Orivet Partners with Sitruna to Expand Ecommerce Footprint in Europe – PR Web

Spanish scientists combine genetic and imaging data to improve the treatment of dilated cardiomyopathy – EurekAlert

Posted: July 27, 2022 at 3:07 am

image:Study codirectors Dr. Pablo Garca-Pava and Dr. Jess Gonzalez Mirelis. view more

Credit: CNIC

Combining a persons genetic profile with imaging data obtained by cardiac magnetic resonance accurately predicts the prognosis of patients with dilated cardiomyopathy, the most frequent cause of heart failure.

This is the finding of a Spanish study published in the European Journal of Heart Failure and coordinated by Dr. Pablo Garca-Pava, investigator at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), a cardiologist at Hospital Puerta de Hierro Majadahonda in Madrid, and a member of the Spanish research network on cardiovascular disease (CIBERCV). The study is the largest in the world to correlate the genetic profiles of dilated cardiomyopathy patients with cardiac magnetic resonance data collected over a long follow-up period.

Dilated cardiomyopathy is the most frequent cause of heart disease in young people and the leading cause of heart transplantation in the world. The disease affects 1 person in every 250 of the general population and is characterized by an enlargement of the heart accompanied by a decline in its capacity to pump blood.

Patients with this condition are at high risk of arrhythmias and sudden cardiac death.

The study examined genetic data collected from 600 patients in 20 Spanish hospitals between 2015 and 2020. The investigators demonstrated that a combination of specific genetic traits with the presence of fibrosis detected by cardiac magnetic resonance imaging accurately identifies those patients who will develop malignant arrhythmias or severe complications of heart failure.

Dr. Jess Gonzalez Mirelis, a cardiologist at Hospital Puerta de Hierro and codirector of the study, explained that there is currently a lack of good prognostic markers for patients with dilated cardiomyopathy. As a result, to prevent sudden death, patients are routinely selected for more aggressive interventions, such as the placement of a defibrillator device, based on the degree of weakening of the hearts pumping action.

The new study shows that classifying patients according to their genetic profile and the presence of fibrosis detected by cardiac magnetic resonance imaging gives a much more accurate indication of patient risk than the extent of weakening of cardiac pumping capacity, the method used until now; the problem with the current method is that some patients with low-grade cardiac weakening develop complications, whereas others with extensive weakening are stable and dont develop problems over the long term, said Dr. Garca Pava.

The researchers found that patients lacking genetic alterations and showing no sign of fibrosis had a very good prognosis, with little risk of sudden death irrespective of the weakening of cardiac pumping capacity.

According to the authors, the study opens the way to a more personalized approach to dilated cardiomyopathy, with each patient receiving the most appropriate treatment based on a precise cardiological assessment.

The findings of this study allow dilated cardiomyopathy patients to be treated according to their specific characteristics and open the way to the application of personalized medicine in this area of cardiology, concluded Dr. Garca-Pava.

The following centers participated in the study: Hospital Universitario Puerta de Hierro, IDIPHISA; CIBER Cardiovascular; Hospital General Universitario Gregorio Maran; Instituto de Investigacin Biomdica de Salamanca (IBSAL)- Complejo Asistencial Universitario de Salamanca; Universidad de Salamanca; Hospital Universitario Virgen de la Arrixaca de Murcia; Hospital Universitari Vall d'Hebron, Vall d'Hebron Instituto de Recerca (VHIR), Universitat Autonoma de Barcelona; Complejo Hospitalario de Navarra; Instituto de Investigacin Biomdica de A Corua (INIBIC), Complexo Hospitalario Universitario de A Corua; Universidad de A Corua; Complejo Hospitalario Universitario de Cceres; Hospital Universitario Virgen de la Victoria IBIMA, Mlaga; Instituto de Ciencias del Corazn (ICICOR); Hospital Clnico Universitario Valladolid; Hospital General Universitario de Alicante, Instituto de Salud e Investigacin Biomdica; Hospital Universitario 12 de Octubre, Instituto de Investigacin i+12; Hospital Clnico, IDIBAPS, Universitat de Barcelona; Instituto de investigacin Sanitaria de Santiago; Complexo Hospitalario Universitario de Santiago; Hospital Universitario Virgen de las Nieves; Hospital Universitario Son Llatzer & IdISBa; Hospital Universitario Virgen del Roco; Hospital Univesitari Dr. Josep Trueta; Instituto del Corazn & Hospital Universitario Germans Trias, and Universidad Francisco de Vitoria (UFV).

The study was funded by grants from the Instituto de Salud Carlos III with cofunding from the European Regional Development Fund (A way to build Europe) and the European Social Fund (Investing in Your Future).

About the CNIC

The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentn Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.

European Journal of Heart Failure

Randomized controlled/clinical trial

People

Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy

22-Jul-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Spanish scientists combine genetic and imaging data to improve the treatment of dilated cardiomyopathy - EurekAlert

Posted in Genetic medicine | Comments Off on Spanish scientists combine genetic and imaging data to improve the treatment of dilated cardiomyopathy – EurekAlert

BU researcher receives $3.9M NIH grant to examine the impact of racism on brain aging, cardiovascular disease risk among older black adults -…

Posted: July 27, 2022 at 3:07 am

(Boston)Black Americans are twice as likely as white Americans to have Alzheimers disease (AD) independent of genetic risk. Since perceived racism contributes to racial health disparities in cardiovascular disease (CVD) risk factors, which also are risk factors for AD,it also has a significant impact on the racialhealth disparity in AD. Despite this knowledge, little is known about whether and how chronic experiences of racism contribute to poor brain health.

Karin Schon, PhD, assistant professor of anatomy & neurobiology at Boston University School of Medicine (BUSM), aims to address this pressing issue. She has been awarded a five-year, $3.9 million R01 grant from the National Institutes of Health. Her objective is to investigate the impact of racism burden on brain health in themedial temporal hippocampal (MTH) memory and prefrontal-executive systems in older Black adults and to examine potentially underlying biological mechanisms. The MTH and prefrontal systems are brainsystems that show profound neurodegeneration in AD.

We hypothesize that cognitively healthy Black seniors with higher racism burden will show greater CVD risk and poorer MTH and prefrontal system integrity than those who have lower lifetime racism burden, explained Schon who also is a faculty affiliate at the BU Center for Anti-Racist Research.

Schon believes that CVD risk and mental health may explain the relationship between racism burden and neurocognitive integrity, suggesting poor cardiovascular/cerebrovascular healthas a mechanism underlying the relationship between racism burden and poor brain health in the MTH and prefrontal brain systems in Black seniors.

Her investigative team is not only diverse in expertise, but also racially and ethnically. Collaborators on this project include BUs Yvette Cozier, DSc; Robert Stern, PhD; Emelia Benjamin, MD and Yorghos Tripodis, PhD. BU alumna Uraina Clark, PhD from Icahn School of Medicine at Mount Sinai along with Angie Sanchez, MD and Jonathan Jackson, PhD from Massachusetts General Hospital.

Schon, received a joint BA/MA degree in psychology from the University of Hamburg in Germany in 1998 and her PhD from the department of psychology at Boston University in 2005. Her dissertation focused on functional neuroimaging studies of working memory and long-term (episodic) memory formation. In 2010, she received a Pathway to Independence Career Development award from the National Institute on Aging to investigate the effects or cardio-respiratory fitness and exercise on the function and structure of the medial temporal hippocampal memory system. In 2013, she joined BUSMs department of anatomy & neurobiology where she is the Director of the Brain Plasticity and Neuroimaging Laboratory.

Her brain plasticity research focuses on modulators of the MTH system across the lifespan. Currently, she is investigating the role of aerobic exercise, aging and chronic psychosocial stress, as modulators of cognitive function and brain health in aging and AD. With her cognitive neuroscience research on chronic psychosocial stress she aims to take an anti-racist perspective by focusing on the impact of interpersonal and institutional racism on brain health in Black adults. The long-term goal of this research to contribute to health policy change from a cognitive neuroscience perspective with the goal to eliminate brain health inequities.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
BU researcher receives $3.9M NIH grant to examine the impact of racism on brain aging, cardiovascular disease risk among older black adults -...

Posted in Genetic medicine | Comments Off on BU researcher receives $3.9M NIH grant to examine the impact of racism on brain aging, cardiovascular disease risk among older black adults -…

Red Biotechnology Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee – This Is Ardee

Posted: July 27, 2022 at 3:06 am

New Jersey, United States This Red Biotechnology Market research works as the best evaluation tool to track the progress of the industry and keep an eye on the competitors growth strategies. It further helps to keep you ahead of your business competitors. This report depicts a few potential problems and gives solutions to them by doing comprehensive research on the market scenario. Valuable information is provided here about a particular market segment according to product type, application, region type, and end user. By referring to this comprehensive Red Biotechnology market analysis report, it becomes possible for organizations to monitor the efficiency of sales, determine the quality of services offered by competitors, estimate the competition level in the market and understand the communication channels followed by competitors in the market.

This Red Biotechnology Market research report covers career outlooks, regional marketplaces, and an overview of the expectations of a number of end-use sectors. With the help of relevant market data, key organizations are able to obtain a competitive benefit over the competitors in the market and attain the best results for business growth. Furthermore, this Red Biotechnology market analysis report emphasizes doing a comparison between several various geographical markets in key regions such as North America, Europe, Middle East, Africa, Latin America, and Asia Pacific. It aims at covering complex structures to classifications to an easy-to-follow overview of different business sectors.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=11405

Key Players Mentioned in the Red Biotechnology Market Research Report:

Amgen Inc., F. Hoffmann-La Roche, Gilead Sciences Inc., CSL, Pfizer Inc.

A massive amount of information presented in this Red Biotechnology Market report helps business players to make beneficial decisions. Some of the major key aspects covered in this market analysis are key performance indicators, customer acquisition, and manufacturers list. Performance results of the marketing plan are also covered in this market analysis report. This market study report enables to bring the improvements required in the business. It further talks about how COVID-19 caused huge trauma in several major sectors. Key marketing channels, market growth opportunities, core marketing strategy, and current scope of the business are some of the major factors discussed in this report. It further briefs on the current position of the market. It depicts the effect of metrics on market trends, revenue, and leads.

Red BiotechnologyMarket Segmentation:

Red Biotechnology Market, By Product Type

Gene Recombinant Drugs Human Vaccines Blood Products Diagnostics Reagents Personalized Medicines Others

Red Biotechnology Market, By Application

Drug Discovery Drug Protection Genetic Testing Pharmacogenomics Gene Therapy Others

Red Biotechnology Market, By End User

Biopharmaceutical Business Research Organizations CMOs and CROs Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=11405

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Red Biotechnology market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Red Biotechnology market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Red Biotechnology market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Red Biotechnology market by application, it gives a study on the consumption in the Red Biotechnology market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Red Biotechnology market are profiled in this section. The analysts have provided information about their recent developments in the Red Biotechnology market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Red Biotechnology market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Red Biotechnology market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Red Biotechnology market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read more here:
Red Biotechnology Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This Is Ardee

Posted in Biotechnology | Comments Off on Red Biotechnology Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee – This Is Ardee

Part 1: Carey Gillam Reporter turned organic propagandist who twists science in her campaign to discredit biotechnology and conventional agriculture…

Posted: July 27, 2022 at 3:06 am

With links to the Church of Scientology, anti-vaccine glyphosate litigator Robert F. Kennedy, Jr., Organic Consumers Association, US Right to Know, and Environmental Working Group, this former Reuters reporter has spearheaded the effort by organic promoters to discredit GMOs, glyphosate, and other agri-technological tools positioned to feed a growing global population and address climate change. Heres her story and why she does it.

Corey Booker has a new-found campaign: Capitalizing on public concerns about the weedkiller glyphosate (also sold under a now-expired patent by Monsanto as Roundup), claimed by its critics to cause cancer. Last Tuesday (June 19), the New Jersey Senator, head of the Committee on Agriculture, Nutrition and Forestry, participated in a webinar highlighting its alleged dangers.

The event was organized by a group called Farmers Footprint, which promotes regenerative and organic agriculture. If you believe the host, this panel was crafted to put dialogue over consensus and allow for the nuance and present all the different perspectives on how glyphosate affects planetary health.

That would have been a constructive conversation to have. Thats the opposite of what happened. To say that the webcast was rigged would be an understatement. No farmers, soil expert or independent regulators were invited. No epidemiologists or toxicologists. Just activists, including someone who goes under the name Glyphosate Girl. And, of course, Booker. And in case you werent sure about where the host stood on the glyphosate controversy, if you scrolled down on the event page at the hosts site, there was this:

The glyphosate attack seminar traces to an article by Carey Gillam in the UK The Guardian earlier in July. The piece reported on the routine release of years-old Centers for Disease Control data, which Gillam claimed (although the figure is not cited in the CDC release) found that 80% of Americans had traces of glyphosate in their urine.

Gillams piece was quickly disseminated by the usual leftwing channels but also became a favorite of the far right, from the Gospel News Networkto The Epoch Times, which makes the case that the government is untrustworthy. Shes beloved by activists, particularly those reflexively critical of Big Agriculture and advocates of organic farming. She was drafted by Farmers Footprint to moderate and guide the webinar.

The event went as would be expected. Glyphosate is a hidden killer. The agricultural industry conspires to hide the facts. The US EPA and other global agencies that have determined the herbicides is safe as used are part of a global conspiracy.

Booker bit. Three days later, he released a statement co-signed by eight Democratic senators, urging the US Fish and Wildlife Service to sharply restrict the use of glyphosate and other long-approved pesticides on National Wildlife Refuges without even suggesting what safer alternatives could be substituted. (There arent any.)

The original report and the seminar were panned by independent scientists. Why? Isnt the presence of a weedkiller in the human body something to be concerned about?

On the surface yes, but the article doesnt really address that threat, which turns out to be minimal to non-existent. Scientists were particularly critical by such exaggerations as disturbing and tied to cancer claims that most independent scientists would reject as hyperbolic or outright incorrect.

As independent scientists Geoffrey Kabat and Kevin Folta wrote in separate articles on the GLP, the numbers as reported by the CDC underscore the relative safety of glyphosate not its possible harmfulness. Micro-traces at infinitesimally small levels in the parts per billion (equivalentto 1 drop of impurity in 500 barrels of water or 1 cent out of $10 million) are no cause for concern. The human body always has potentially harmful substances but at levels too low to be actually harmful. For example, human tissues and blood normally contain small amounts of various radioactive isotopes, which are harmless at the levels at which they occur. Any lab could identify thousands of purportedly toxic chemicals

Specifically, our kidneys are designed to eliminate potential toxins. The presence of micro-traces of any of thousands of toxins in our urine, including glyphosate, is a reassuring sign that our body is functioning properly. The level of glyphosate found in this study is detectablebut negligible and harmless, as regulatory agencies worldwide have determined.

While science was not on the agenda, the article and panel did provide a star turn for Gillam. In her current position, she partners with the Environmental Working Group, an organic-industry funded activist and litigation-focused organization in producing a blog called The New Lede. She refers to herself on her LinkdedIn page as a modern-day Rachel Carson for her groundbreaking work in exposing decades of corporate secrets and deceptive tactics by powerful pesticide companies, including the global giant Monsanto.

In fact, Gillam has had a rocky professional history. Scientists call her a one-woman science wrecking ball who misunderstands chemical risk and systematically exaggerates the dangers of a weedkiller that the global regulatory community has unanimously determined is safe as used, both to human health and the environment. Well have more on glyphosate, the article, Gillams history, and The New Lede as we go along.

If you are not familiar with the global conversation surrounding glyphosate, it has become a touchstone in the debate over the future of farming. The weedkillers proponentsupwards of 98% of the worlds farmers and every major independent regulatory or oversight agency in the world, (19 of them), subscribe to the science that the weedkiller is safeboth in the environment and as it shows up in micro-traces in food.

One UN sub-agency, the International Agency for Research on Cancer (IARC), singularly strayed from the consensus and issued a hazard analysis, which does not evaluate real-life exposure [all 19 of the other agencies did a risk analysis, which evaluates the actual likelihood of getting cancer under real-life conditions; for an explanation, read this]. It concluded that the weedkiller poses a theoretical hazard to everyday applicators who apply it over many years or decades but drew no conclusion as to its trace risks in food.

[View hyperlinked GLP infographic to review the findings by the global agencies].

Nineteen of the 20 independent agencies reviewed IARCs hazard data in 23 studies and found its findings incomplete and its research methods shoddy or inadequate. As Health Canada recently noted (2019) after reviewing claims that glyphosate causes health problems:

No pesticide regulatory authority in the world currently considers glyphosate to be a cancer risk to humans at the levels at which humans are currently exposed.

That hasnt stopped the debate over the weedkiller from percolating in the media and in legislative halls, pitting the global regulatory and science community against activist groups who target synthetic agricultural chemicals (many of which are safer with less consequences to the environment, flora and fauna then organic alternatives). Risk in chemicals is challenging for most people to assess, which is why extremist activists like EWG and Gillam view targeting pesticides as the public-relations Achilles heel of mainstream agriculture as they seek to promote organic and regenerative farming.

Contradicting what the discussion on Gillams webcast suggested, exposure to glyphosate traces in our urine is not unusual almost any common toxic chemical shows up in parts per billion. As the chart below illustrates, Vitamin D is potentially hundreds of times more threatening. Glyphosate is less toxic than table salt. The caffeine in your morning cup of Joe is 22 times more toxic than the weedkillerbut like glyphosate, toxic caffeine is excreted from our bodies, harmlessly. Thank you, kidneys!

Since ancient times, it has been known that the dose makes the poison. Chemical risk comes down to how much we are exposed to and how long. And as Dr. Kabat reported in his article, the state-of-the art National Cancer Institutes Agricultural Health Study, which tracked farm workers exposed to glyphosate over decades, showed no association of glyphosate with any of more than twenty types of cancer.

So, despite the noise created by Gillam and activist groups, no reputable oversight or assessment agency in the worldnot oneconsiders trace levels of glyphosate as noted in our urine at the levels cited by the CDC as potentially harmful.

A recent similar urine analysis report, drawing on the same CDC database, on another herbicide conducted by a group called the Heartland Study was exposed in this article by Cornell microbiologist Dr. Kathleen Hefferon. It had similar methodological flaws and serious academic ethical breaches. The analysis was led by glyphosate litigation consultant Charles Benbrook [Read GLP profile of Benbrook]. Benbrook, an economist with no formal background in toxicology, is known in legal circles as an anti-chemical consultant for hire when organic clients want removed from the market).

The CDC report would have been a footnote in a mountain of mostly useless data until it was weaponized by Carey Gillam.Besides her skewed analysis that ran in The Guardian, she placed it at her partner organizations accompanied: on EWGs site (which exaggerated the data, claiming CDC found 87%); and on vaccine denier Robert F. Kennedys Childrens Health Defense e-mag, The Defender, for which Gillam writes regularly and has a dedicated column page. (The Defender is committed to defending children from getting life-saving routine vaccines, including COVID vaccines.)

Carey Gillam has been the most visible and relentless critic of agricultural chemicals for a decade. What is her background? What follows is a more accurate primer on her background.[Read GLP backgrounder of one of Gillams books here]

Gillam has a history as a longtime Monsanto antagonist and critic of conventional agriculture. She was affiliated with Reuters for 17 years, much of it covering food and farming in the Midwest. According to Freedom of Information documents, she left under a cloud after being confronted by her editor in 2015, after years of complaints from independent scientists about her lack of editorial balance and her embrace of anti-GMO conspiracy propaganda. Her anti-GMO activist friends were well aware that editors at Reuters had challenged her for apparently compromising journalistic standards and ethics.

When contacted by the GLP, Gillam denied being forced out under pressure from Reuters management, claiming she has paperwork to support her claim, but she refused to share it.Shortly after leaving Reuters, Gillam was named research director at US Right to Know, where the constraints of objective journalism that she reportedly challenged were no longer in place.

Tomorrow, we will examine Carey Gillams work as a frontperson for the anti-GMO industry and the web of pro-organic corporations and activist groups that profit from her advocacy.

Jon Entineis the foundingexecutivedirectorof theGenetic Literacy Project, and winner of 19 major journalism awards. He has written extensively in the popular and academic press on media ethics, corporate social responsibility, sustainability, and agricultural and population genetics. You can follow him on Twitter@JonEntine.The GLP discloses all major contributors and conflicts of interest, and outlines its donor policy on itstransparency page.

Continue reading here:
Part 1: Carey Gillam Reporter turned organic propagandist who twists science in her campaign to discredit biotechnology and conventional agriculture...

Posted in Biotechnology | Comments Off on Part 1: Carey Gillam Reporter turned organic propagandist who twists science in her campaign to discredit biotechnology and conventional agriculture…

Page 326«..1020..325326327328..340350..»